Cargando…
Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment
Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear. Therefore, this study assessed the risk of rosuvastatin-induced QT prolongation using (1) real-wo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199059/ https://www.ncbi.nlm.nih.gov/pubmed/37208484 http://dx.doi.org/10.1038/s41598-023-35146-z |
_version_ | 1785044851280052224 |
---|---|
author | Koo, Yeryung Hyun, Sung-Ae Choi, Byung Jin Kim, Yujeong Kim, Tae Young Lim, Hong-Seok Seo, Joung-Wook Yoon, Dukyong |
author_facet | Koo, Yeryung Hyun, Sung-Ae Choi, Byung Jin Kim, Yujeong Kim, Tae Young Lim, Hong-Seok Seo, Joung-Wook Yoon, Dukyong |
author_sort | Koo, Yeryung |
collection | PubMed |
description | Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear. Therefore, this study assessed the risk of rosuvastatin-induced QT prolongation using (1) real-world data with two different settings, namely case–control and retrospective cohort study designs; (2) laboratory experiments using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM); (3) nationwide claim data for mortality risk evaluation. Real-world data showed an association between QT prolongation and the use of rosuvastatin (OR [95% CI], 1.30 [1.21–1.39]) but not for atorvastatin (OR [95% CI], 0.98 [0.89–1.07]). Rosuvastatin also affected the sodium and calcium channel activities of cardiomyocytes in vitro. However, rosuvastatin exposure was not associated with a high risk of all-cause mortality (HR [95% CI], 0.95 [0.89–1.01]). Overall, these results suggest that rosuvastatin use increased the risk of QT prolongation in real-world settings, significantly affecting the action potential of hiPSC-CMs in laboratory settings. Long-term rosuvastatin treatment was not associated with mortality. In conclusion, while our study links rosuvastatin use to potential QT prolongation and possible influence on the action potential of hiPSC-CMs, long-term use does not show increased mortality, necessitating further research for conclusive real-world applications. |
format | Online Article Text |
id | pubmed-10199059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101990592023-05-21 Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment Koo, Yeryung Hyun, Sung-Ae Choi, Byung Jin Kim, Yujeong Kim, Tae Young Lim, Hong-Seok Seo, Joung-Wook Yoon, Dukyong Sci Rep Article Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear. Therefore, this study assessed the risk of rosuvastatin-induced QT prolongation using (1) real-world data with two different settings, namely case–control and retrospective cohort study designs; (2) laboratory experiments using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM); (3) nationwide claim data for mortality risk evaluation. Real-world data showed an association between QT prolongation and the use of rosuvastatin (OR [95% CI], 1.30 [1.21–1.39]) but not for atorvastatin (OR [95% CI], 0.98 [0.89–1.07]). Rosuvastatin also affected the sodium and calcium channel activities of cardiomyocytes in vitro. However, rosuvastatin exposure was not associated with a high risk of all-cause mortality (HR [95% CI], 0.95 [0.89–1.01]). Overall, these results suggest that rosuvastatin use increased the risk of QT prolongation in real-world settings, significantly affecting the action potential of hiPSC-CMs in laboratory settings. Long-term rosuvastatin treatment was not associated with mortality. In conclusion, while our study links rosuvastatin use to potential QT prolongation and possible influence on the action potential of hiPSC-CMs, long-term use does not show increased mortality, necessitating further research for conclusive real-world applications. Nature Publishing Group UK 2023-05-19 /pmc/articles/PMC10199059/ /pubmed/37208484 http://dx.doi.org/10.1038/s41598-023-35146-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Koo, Yeryung Hyun, Sung-Ae Choi, Byung Jin Kim, Yujeong Kim, Tae Young Lim, Hong-Seok Seo, Joung-Wook Yoon, Dukyong Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title_full | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title_fullStr | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title_full_unstemmed | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title_short | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
title_sort | evaluation of rosuvastatin-induced qt prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199059/ https://www.ncbi.nlm.nih.gov/pubmed/37208484 http://dx.doi.org/10.1038/s41598-023-35146-z |
work_keys_str_mv | AT kooyeryung evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT hyunsungae evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT choibyungjin evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT kimyujeong evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT kimtaeyoung evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT limhongseok evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT seojoungwook evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment AT yoondukyong evaluationofrosuvastatininducedqtprolongationriskusingrealworlddatainvitrocardiomyocytestudiesandmortalityassessment |